èšåºæ®µéã®ãã€ãªå»è¬åäŒç€Ÿã§ãã Cyclacel Pharmaceuticals, Inc. ã¯ãããããã®ä»ã®å¢æ®æ§çŸæ£ã®æ²»çè¬ãéçºããŠããŸããå瀟ã®è
«çéçºããã°ã©ã ã«ã¯ãåºåœ¢è
«çã®æ²»çããã³åçºæ§ãŸãã¯é£æ²»æ§ã®æ
¢æ§ãªã³ãæ§çœè¡ç
ã®æ²»çã«ãããã¯ã©ãã¯ã¹ãšã®äœµçšã§ãã§ãŒãº I èšåºè©Šéšäžã§ãããµã€ã¯ãªã³äŸåæ§ãããŒãŒé»å®³å€ (CDK) ã®ãã¡ãã©ã·ã¯ãªããããã³é²è¡æ§çœè¡ç
ã®æ²»çã«ãã§ãŒãº I èšåºè©Šéšäžã§ããããæ§ãããŒãŒé»å®³å€ããã°ã©ã ã® CYC140 ããããŸããå瀟ã®è
«çéçºããã°ã©ã ã«ã¯ãæ°èŠãã¯ã¬ãªã·ãé¡äŒŒäœã§ãã CNDAC ã®çµå£æäžå¯èœãªãããã©ãã°ã§ãããµãã·ã¿ãã³ãå«ãŸããŠããŸããããã«ãå瀟ã®è
«çéçºããã°ã©ã ã«ã¯ CDK é»å®³å€ã®ã»ãªã·ã¯ãªããå«ãŸããŠããŸããå瀟ã¯ãããµã¹å€§åŠMDã¢ã³ããŒãœã³ããã»ã³ã¿ãŒãšèšåºååå¥çŽãçµã³ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãæ¥æ§éªšé«æ§çœè¡ç
ã骚é«ç°åœ¢æçå矀ããã®ä»ã®é²è¡æ§çœè¡ç
ãå«ãè¡æ¶²æªæ§è
«çã®æ£è
ã察象ã«ã3çš®é¡ã®ãµã€ã¯ã©ã»ã«å»è¬åã®å®å
šæ§ãšæå¹æ§ãèšåºçã«è©äŸ¡ããŠããŸãããµã€ã¯ã©ã»ã«ã»ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿã¯1992幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ããŒã¯ã¬ãŒã»ãã€ãã«æ¬ç€Ÿã眮ããŠããŸãã